tradingkey.logo
tradingkey.logo

Johnson & Johnson Files With U.S. FDA To Include New Evidence In TREMFYA®(Guselkumab) Label As The Only Il-23 Inhibitor To Demonstrate Significant Inhibition Of Joint Structural Damage In Active Psoriatic Arthritis

ReutersJul 29, 2025 1:50 PM

- Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON FILES WITH U.S. FDA TO INCLUDE NEW EVIDENCE IN TREMFYA® (GUSELKUMAB) LABEL AS THE ONLY IL-23 INHIBITOR TO DEMONSTRATE SIGNIFICANT INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI